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Abstract
Background: HER-2/neu and c-kit (CD117) onco-protein are increasingly being recognized as
targets for therapy in solid tumors, but data on their role in malignant melanoma is currently
limited. We studied the prevalence of overexpression of HER-2/neu and c-Kit in 202 patients with
malignant melanoma to evaluate a possible prognostic value of these molecular targets in malignant
melanoma.
Methods: Overexpression of HER-2/neu and c-Kit was evaluated using immunohistochemical
assays in 202 archival tissue specimens.
Results: Between 1991 and 2001, 202 subjects (109 males; 54% and 93 females; 46%) with
malignant melanoma were studied with a mean age of 57 years (age range: 15–101 years). The most
common histologic type was amelanotic melanoma (n = 62; 30.7%) followed by superficial spreading
melanoma (n = 54; 26.7%). The depth of penetration of melanoma (Breslow thickness, pT Stage)
ranged from 0.4 mm (stage pT1) to 8.0 mm (stage pT4A). Mean thickness was 2.6 mm (stage pT3A).
The ECOG performance scores ranged from 0 to 3. Only 2 patients (0.9%) revealed HER-2/neu
overexpression, whereas 46 (22.8%) revealed c-Kit overexpression. Multivariate analysis
performed did not show a significant difference in survival between c-Kit positive and negative
groups (p = 0.36). Interestingly, not only was c-Kit more likely to be overexpressed in the
superficial spreading type, a preliminary association between the presence or absence of c-Kit
overexpression and the existence of another second primary tumor was also observed.
Conclusions: The results of our large study indicate that the HER-2/neu onco-protein neither has
a role in melanogenesis nor is a potential target for clinical trials with monoclonal antibody therapy.
This indicates there is no role for its testing in patients with malignant melanoma. Although c-Kit,
expressed preferentially in the superficial spreading type, may not have prognostic value, it does
have significant therapeutic implications as a molecular target warranting further investigation.
Background
The molecular basis of human malignant melanoma pro-
gression has remained largely unknown despite the fact
that the incidence of melanoma is rapidly increasing [1].
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Current staging methods have limitations in their ability
to accurately identify all of the patients who will develop
melanoma metastases making the targeting of therapeutic
interventions very important. These limitations, along
with the poor prognosis once metastases are discovered,
have led to the recent emphasis on the study of melanoma
genetics. Melanoma development from genomic altera-
tions has been classified into either tumor suppressors,
that are down-regulated with malignant transformation,
or oncogenes, whose functions are up-regulated. It is
believed that oncogenes often represent activated growth
factor or growth factor receptor genes. Mutations at the
proto-oncogenic loci can lead to enhanced gene product
function and provide the needed substrate for an
increased susceptibility to malignant conversion [2]. Sev-
eral attempts have been made to identify various prognos-
tic and diagnostic molecular factors like HER-2/neu and c-
Kit (CD117) in patients with malignant melanoma. How-
ever, to date, there is limited and contradictory informa-
tion available in the literature regarding the role of these
possible molecular targets for cancer therapy.
HER-2/neu proto-oncogene was originally isolated from a
human mammary carcinoma and a salivary gland adeno-
carcinoma as an amplified gene related to but distinct
from epidermal growth factor (EGF) receptor. HER-2/neu
oncogene encodes a 185-kDa cell surface glycoprotein,
which has intrinsic tyrosine kinase activity with multiple
transduction pathways and involvement in the regulation
of cell growth and differentiation [3]. The overexpression
of HER-2/neu has been demonstrated in a variety of
malignancies including breast, ovarian, lung, gastric,
endometrial, and glioblastomas [4–8]. However, the
extent to which HER-2/neu is overexpressed in melano-
mas is unclear. There have been a few smaller studies done
to demonstrate the status of HER-2/neu overexpression in
malignant melanoma [9–12]. A recent study demon-
strated that emodin, a tyrosine kinase inhbitor, can
inhibit HER-2/neu's tyrosine kinase activity and block the
increase of HER-2/neu-overexpressing cells in nude mice
and culture. This study also targeted the HER-2/neu pro-
moter in tumor-bearing mice resulting in extended sur-
vival with suppression of tumor [13]. These earlier
findings propose the possibility of using therapeutics to
target HER-2/neu-overexpressing cancer cells.
The proto-oncogene c-Kit encodes a transmembrane tyro-
sine kinase receptor related to the platelet-derived growth
factor PDGF/CSF-1 (c-fms) receptor subfamily [14]. C-Kit
has been found to play a pivotal role in the normal growth
and differentiation of embryonic melanoblasts. Muta-
tions in c-Kit and its ligand result in white spotting in mice
and humans [15,16]. Malignant transformation of
melanocytes is associated with changes in the expression
of the c-Kit receptor. Several studies have demonstrated
that the progression of human melanoma is associated
with the loss of expression of the c-Kit proto-oncogene
[17–19]. These studies revealed that expression of the
tyrosine kinase receptor encoded by the c-KIT proto-onco-
gene gradually declines during the tumor growth and
invasion of human melanoma. The explanation for the
loss of c-KIT gene expression in melanoma advancement
has still not been fully explained. Recent research looked
at the correlation between c-KIT expression and a tran-
scription factor, AP-2, that binds to the c-KIT promotor.
Results signified c-KIT expression was directed by AP-2
and AP-2 expression suppressed tumorigenicity and met-
astatic potential of human melanoma cells [20]. These
findings emphasize the importance of this proto-onco-
gene's role as a molecular target in melanogenesis.
Since HER-2/neu and CD117 (c-Kit) are now potential
targets for site-specific therapy in certain solid tumors, the
identification of overexpression of the above mentioned
markers by standard immunohistochemical techniques
would be a significant scientific advance in our under-
standing of melanogenesis. This could possibly lead to the
development of effective treatment protocols for patients
with malignant melanoma. Hence, we analyzed overex-
pression of HER-2/neu and c-Kit in 202 patients with
biopsy-proven malignant melanoma to determine their
prevalence and to evaluate their possible role in malig-
nant melanoma.
Methods
After appropriate approval from our institutional review
board, a retrospective study was initiated to review the
medical records of all patients with a diagnosis of malig-
nant melanoma between 1991 and 2001. An extensive
chart review was performed to collect relevant patient
demographic and clinical data to include: age, gender,
smoking history, presenting symptom(s), histological
type, Breslow stage at diagnosis, performance status
(ECOG score) at presentation, stage of the melanoma,
modality/type of therapy, associated primary malignan-
cies and survival. HER-2/neu and c-Kit overexpression
were assayed using immunohistochemical techniques
(IHC) on archival tissue specimens.
HER-2/neu testing
HER-2/neu testing was performed using the most widely
used technique for assessment of HER-2/neu status i.e.
immunohistochemistry (IHC), which measures overex-
pression of the HER-2/neu onco-protein. IHC was carried
out on formalin fixed, paraffin embedded material, using
the Hercep test developed by DAKO. Immunostaining
was classified as follows: 0 = no staining, 1+ = faint,
incomplete membranous pattern, 2+ = moderate, com-
plete membranous pattern, 3+ = strong membranous pat-
tern [21]. A trained pathologist who was blinded from theJournal of Carcinogenesis 2003, 2 http://www.carcinogenesis.com/content/2/1/8
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clinical history of the patient interpreted these results. An
IHC score of 2+ or greater was considered as HER-2/neu
overexpression [22].
CD117 (c-Kit) testing
C-Kit testing was also performed using IHC and recorded
on a semi-quantitative scale: the number of positive cells
(0%, <10%, 10–50%, and >50%) and the intensity of the
reaction. C-Kit results were interpreted by a single pathol-
ogist (S.K.) who was blinded from the clinical data, and
reported as positive/negative. Immunohistochemical
staining for KIT (CD117) was performed using a 1:250
dilution of the rabbit polyclonal antibody A4502
(IMPATH, CA) with the EnVision detection system. Anti-
gen retrieval method was not utilized. Appropriate posi-
tive and negative controls were used throughout the
testing process. For the purposes of our present study, we
used the rabbit polyclonal antibody A4502, which has
shown consistent performance even against a low back-
ground. We selected the A4502 polyclonal antibody
because it is the most widely used KIT antibody and
because it is the antibody specified for CD117 (c-Kit) test-
ing in the large co-operative clinical trials involving
STI571 (Gleevec®).
Results
Between 1991 and 2001, 202 subjects (109 males; 54%
and 93 females; 46%) with malignant melanoma were
studied. Mean age of the study group was 57 years (age
range: 15–101 years). Sixty-seven (33.1%) were smokers,
108 (53.5%) were non-smokers and in 27 (13.4%)
patients, smoking history was not documented. The most
common histologic type was amelanotic melanoma (n =
62; 30.7%) followed by superficial spreading melanoma
(n = 54; 26.7%). The ECOG performance scores ranged
from 0 to 3. Other histologic types identified in the study
group included lentigo maligna melanoma (n = 30;
14.9%), nodular melanoma (n = 27; 13.4%) and acral
lentiginous melanoma (n = 23; 11.4%). The depth of pen-
etration of melanoma (Breslow thickness, pT Stage)
ranges from 0.4 mm (stage pT1) to 8.0 mm (stage pT4A).
Mean thickness was 2.6 mm (stage pT3A). The most com-
mon presenting symptom was change in skin lesion (n =
166; 82.2%) and only 12 patients (5.9%) had evidence of
distant metastasis at presentation. Treatment modalities
Table 1: Demographic and clinical features of c-Kit positive/negative subjects.
c-Kit positive (n = 46) c-Kit negative (n = 156) P-value
Age: 54 years 58 years 0.17*
Sex :
Males n = 109                       26 (23.9%) 83 (76.1%) 0.69**
Females n = 93 20 (21.5%) 73 (78.5%)
Performance Status:
ECOG – 0 n = 87 23 (26.4%) 64 (73.6%)
ECOG – 1 n = 65 24 (36.9%) 41 (63.1%)
ECOG – 2 n = 42 20 (47.6%) 22 (52.4%)
ECOG – 3 n = 8 4 (50%) 4 (50%)
Smoking Status:
Smoker n = 67 13 (19.4%) 54 (80.6%) 0.76**
Non-Smoker n = 108 23 (21.3%) 85 (78.7%)
Unknown n = 27 10 (37.0%) 17 (63.0%)
Second Primary Cancers:
Absent n = 154 41 (26.6%) 113 (73.4%) 0.02**
Present n = 48 5 (10.4%) 43 (89.6%)
Presenting Symptom:
Change in skin lesion n = 166 44 (26.5%) 122 (73.5%) 0.01**
Others n = 19 0 (0.0%) 19 (100%)
Unknown n = 17 2 (11.8%) 15 (88.2%)
Histologic type:
Amelanotic Melanoma n = 62 3 (4.8%) 59 (95.2%)
Superficial Spreading n = 54 29 (53.7%) 25 (46.3%)
Lentigo maligna n = 30 7 (23.3%) 23 (76.7%)
Nodular Melanoma n = 27 4 (14.8%) 23 (85.2%)
Acral lentiginous n = 23 3 (13.0%) 20 (87.0%)
Others/unclassified n = 6 0 (0.0%) 6 (100%)
Mean Breslow thickness 2.9 mm 3.1 mm
Survival (Mean) 96 months 91 months 0.22†
* Test of significance by unpaired t-test † Test of significance by Log Rank Test ** Test of significance by chi-2 testJournal of Carcinogenesis 2003, 2 http://www.carcinogenesis.com/content/2/1/8
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included surgical excision alone or adjuvant chemother-
apy with either single agent DTIC, combination therapy
with CVD (cisplatin, vincristine and dacarbazine), high
dose interferon-alpha or interleukin therapy. HER-2/neu
onco-protein was overexpressed in only 2/202 patients
(0.9%) while c-Kit was overexpressed in 46 patients
(22.8%). Demographic and clinical features of c-Kit posi-
tive subjects are summarized in table 1.
After adjusting for age, sex, smoking status and treatment
history, survival analysis was performed using the Cox
proportional regression model. Survival data was disease
specific to melanoma. Multivariate analysis did not show
a significant difference in survival between the c-Kit posi-
tive and negative groups (p = 0.36) (Figure 1). Sex was a
significant predictor of survival (p = 0.02) in this model.
The mean survival in males was 109 months as compared
to 93 months in females.
Interestingly, c-Kit overexpression was seen in 10.4% (n =
5) of melanoma subjects who also had another co-exist-
ent second primary tumor. Also, absence of c-Kit overex-
pression was statistically related to the absence of other
associated second primary malignancies in patients with
melanoma as c-Kit was overexpressed in only 26.6% (n =
41) of melanoma patients (n = 154) without associated
malignancies (p = 0.01). Among the various sub-types of
melanoma, c-Kit was overexpressed in 29/54 (53.7%) of
patients with superficial spreading melanoma. Also 29/46
(63%) of c-Kit positive patients had superficial spreading
melanoma, indicating that c-Kit overexpression is prefer-
entially seen in the superficial spreading type.
Kaplan-Meier survival analysis by c-Kit status determined by immunohistochemistry Figure 1
Kaplan-Meier survival analysis by c-Kit status determined by immunohistochemistry.Journal of Carcinogenesis 2003, 2 http://www.carcinogenesis.com/content/2/1/8
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Discussion
Despite recent advances in therapy, the morbidity and
mortality associated with malignant melanoma is sub-
stantial. At present there are few useful diagnostic/prog-
nostic markers that are also potential targets for therapy in
patients with malignant melanoma. Overexpression of
HER-2/neu has been established as a poor prognostic
indicator and a target for therapy in a variety of malignan-
cies [4–8]. However, its role in malignant melanoma has
not been defined. Also, several small studies have linked
the loss of expression of proto-oncogene c-Kit with tumor
progression in malignant melanoma [15,16], but its role
as a molecular target has not been explored.
In an attempt to elucidate the role of HER-2/neu and c-Kit
overexpression in malignant melanoma, we analyzed
archival tissue specimens of 202 melanoma cases identi-
fied between 1991 and 2001. IHC was preferred over flu-
orescent in situ hybridization (FISH) since it is a routine,
relatively inexpensive analytic method. It can be per-
formed on the smallest of specimens, including cytologi-
cal specimens, provided tumor cells are present. Also,
interpretation is not influenced by non-tumor material
present in the specimen and this method will not detect
normal low levels of the protein on pathological tissue.
Moreover, IHC is the technique that has been more exten-
sively studied in large clinical trials.
HER-2/neu overexpression
In our series, only 2 of the 202 patients (0.9%) revealed
HER-2/neu overexpression. Previously, Persons et al [23]
reported that HER-2/neu is amplified and overexpressed
in an estimated 0.06% to 13.16% of melanomas. In con-
trast, variable levels of HER-2/neu mRNA were reported
by Easty et al in 19 melanoma cell lines [9] and Cheneuix-
Trench et al reported a low level of HER-2/neu mRNA in
16 additional melanoma cell lines [10]. HER-2/neu was
detected in 5 out of 8 melanoma cell lines as analyzed by
flow cytometry by Rongcum and co-workers [11]. Bodey
et al performed the largest previous study using IHC and
reported that HER-2/neu was expressed in 12 out of 30
primary cutaneous malignant melanomas and 8 out of 10
metastatic malignant melanomas [24]. There are various
reasons for the discordant results between these studies.
The use of established cell lines causes induction of
expression of HER-2/neu during culture. Therefore, meas-
uring the presence of HER-2/neu mRNA may not directly
correspond to overexpression of HER-2/neu protein. Also,
differences in fixation techniques, differences in epitope
and antigen retrieval methods employed and differences
in the sensitivity of the particular antibody used in detect-
ing the HER-2/neu onco-protein can account for the dis-
cordant results between the various smaller studies [25].
Our study, using the semi quantitative immunohisto-
chemical assay (DAKO Hercep kit), is the largest study
suggesting that overexpression of HER-2/neu onco-pro-
tein does not commonly occur in malignant melanoma.
Therefore, our findings show HER-2/neu has no value as
a biomarker or as a molecular target for immunotherapy
in patients with melanoma.
CD117 (c-Kit) overexpression
The c-Kit proto-oncogene is a transmembrane tyrosine
kinase type receptor that is crucial for melanocyte devel-
opment and proliferation [17,18,26,27]. Several smaller
studies have addressed c-Kit expression in malignant
melanomas. Larue et al [27] observed that mutation of the
c-Kit gene in murine models could result in malignant
transformation with production of tumors similar to
amelanotic melanoma. Lassam and Bickford [17], Natali
et al [18] and Zakut et al [19] suggested that c-Kit expres-
sion progressively decreases during local tumor growth
and invasion of human melanomas. As opposed to recent
findings in gastrointestinal stromal tumors, lack of c-Kit
expression directly correlates with the metastatic potential
of human melanoma cells in nude mice [28]. In our
study, we analyzed c-Kit overexpression in all 202
melanoma cases using IHC. C-Kit was overexpressed in 46
(22.8%) cases. There was no statistically significant differ-
ence in survival between c-Kit positive and negative
groups and hence no prognostic significance of c-Kit over-
expression was identified. However, c-Kit was overex-
pressed in 53.7% cases of superficial spreading melanoma
(early stage) indicating that c-Kit is overexpressed prima-
rily in the early stage of the disease and downregulation of
c-Kit is likely in metastatic/advanced disease. The mecha-
nism by which malignant melanoma cells lose c-Kit
expression is unclear. The c-Kit gene is neither deleted nor
rearranged in c-Kit negative melanoma cell lines, suggest-
ing that lack of c-Kit overexpression is most likely due to
altered expression of transcription factors [17,19,29].
Huang et al [20] suggested that in metastatic melanoma
cells, lack of c-Kit expression correlates with lack of expres-
sion of the AP-2 transcription factor, and that in
melanoma cells, AP-2 serves as a positive regulator of c-Kit
expression. Our study results indicate that c-Kit overex-
pression has no prognostic value in patients with malig-
nant melanoma. However, the identification of c-Kit in a
significant proportion of our patient population could
possibly have important therapeutic implications for
future clinical trials evaluating the role of site-specific
therapies in melanoma. As previously discussed, c-Kit was
overexpressed in only 26.6% (n = 41) of the melanoma
patients (n = 154) without associated second primary
malignancies (p = 0.01). Thus, the absence of c-Kit over-
expression is also clinically related to the absence of other
associated primary malignancies in patients with malig-
nant melanoma.Journal of Carcinogenesis 2003, 2 http://www.carcinogenesis.com/content/2/1/8
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From our results, it is now clear that some therapeutic
value but no prognostic value could be potentially found
in the testing of patients with malignant melanoma for c-
Kit overexpression. No value could be found in testing for
HER-2/neu in patients with malignant melanoma. How-
ever, it is important to mention that a major limitation of
our study is the fact that our cohort of patients with malig-
nant melanoma did not include more patients with
diminished survival or early death (Figure 1). More
patients with diminished survivals in the study may have
defined the possible prognostic values better. Future stud-
ies on the role of bio-markers in malignant states would
benefit by evaluating selected matched subgroups of
patients (with and without adverse outcomes). This
would be more likely to define the prognostic association
if any between the individual molecular marker and the
malignant condition.
Conclusions
Despite recent advances in the early detection and treat-
ment of malignant melanoma, the diagnosis of
melanoma is often made after the cancer has already
metastasized to the regional and/or distant lymph nodes,
liver, lung or central nervous system. Since current clinico-
pathologic staging systems enable us to identify only a
proportion of patients with adverse survival characteris-
tics, better clinical/molecular prognostic indicators need
to be identified. Our study, which is the largest study to
date, found that (i) HER-2/neu, although a poor
prognostic indicator in a variety of solid tumors has no
role in melanoma patients; (ii) the presence of c-Kit over-
expression (detected in 22.8% specimens), although not
predictive of survival, is associated with the presence of
second primary tumors in patients with melanoma; (iii)
overexpression of c-Kit is more likely to be seen in the
superficial spreading type; (iv) in a proportion of patients,
the efficacy of target-specific therapies against c-Kit in
malignant melanoma warrants further investigation.
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